ELAHERE DIN 02560771
Health Canada record
| Active ingredient(s) | MIRVETUXIMAB SORAVTANSINE 100 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FX26 MIRVETUXIMAB SORAVTANSINE |
| Original market date | 09-Jan-2026 |
| Current status date | 09-Jan-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35928 | 2025-08-29 | New Drug Submission (NDS) |
Special Access Programme
This molecule appears on Health Canada's list of drugs most often requested through the Special Access Programme.
Request a quote for ELAHERE